In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Hoth Therapeutics Inc (NASDAQ: HOTH) closed at $1.30 in the last session, down -8.45% from day before closing price of $1.42. In other words, the price has decreased by -$8.45 from its previous closing price. On the day, 0.71 million shares were traded.
Ratios:
We take a closer look at HOTH’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.08 and its Current Ratio is at 15.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, The Benchmark Company on October 15, 2019, initiated with a Speculative Buy rating and assigned the stock a target price of $10.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 16 ’24 when Knie Robb bought 25,000 shares for $0.67 per share. The transaction valued at 16,750 led to the insider holds 58,131 shares of the business.
Stock Price History:
Over the past 52 weeks, HOTH has reached a high of $3.80, while it has fallen to a 52-week low of $0.58. The 50-Day Moving Average of the stock is 40.16%, while the 200-Day Moving Average is calculated to be 32.77%.
Shares Statistics:
A total of 13.17M shares are outstanding, with a floating share count of 13.14M. Insiders hold about 0.49% of the company’s shares, while institutions hold 2.30% stake in the company.
Earnings Estimates
The stock of Hoth Therapeutics Inc (HOTH) is currently drawing attention from 1.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.23 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$0.97 and -$0.97 for the fiscal current year, implying an average EPS of -$0.97.
